Plasma cell-derived mtDAMPs activate the macrophage STING pathway, promoting myeloma progression

Aisha Jibril1, Charlotte Hellmich1,2, Edyta E Wojtowicz1,3

  • 1Department of Molecular Haematology, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, United Kingdom.

Blood
|March 8, 2023
PubMed

Insights

Malignant plasma cells release mitochondrial DNA (mtDNA), activating macrophages via STING signaling. This promotes multiple myeloma progression and retains cancer cells in the bone marrow microenvironment.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Mitochondrial damage-associated molecular patterns (mtDAMPs), including cell-free mitochondrial DNA (mtDNA), are potent immune activators.
  • Elevated cell-free mtDNA is observed in trauma and cancer patients, but its role in disease progression is unclear.
  • Multiple myeloma (MM) survival and progression depend on the bone marrow (BM) microenvironment.

Purpose of the Study:

  • To investigate the role of MM cell-derived mtDAMPs in the protumoral BM microenvironment.
  • To elucidate the mechanism and functional consequences of mtDAMPs in myeloma progression.
  • To determine if targeting the mtDAMP-STING pathway impacts MM tumor burden.

Main Methods:

  • Quantified mtDNA levels in peripheral blood serum of MM patients versus healthy controls.
  • Utilized in vivo models (MM1S cells in NOD-SCID gamma mice, KaLwRij-5TGM1 model) to study MM cell-derived mtDNA.
  • Investigated macrophage response to mtDAMPs via the STING pathway and analyzed chemokine signatures.

Main Results:

  • Identified elevated mtDNA in MM patients' serum, originating from MM cells.
  • Demonstrated that BM macrophages sense and respond to mtDAMPs through the STING pathway.
  • Showed that STING pathway inhibition reduces MM tumor burden and that MM-derived mtDAMPs upregulate chemokine signatures, influencing MM cell egress.

Conclusions:

  • Malignant plasma cells release mtDNA into the BM microenvironment, activating macrophages via STING signaling.
  • mtDAMP-activated macrophages promote MM progression and contribute to retaining MM cells within the BM.
  • Targeting the mtDAMP-STING pathway presents a potential therapeutic strategy for multiple myeloma.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...